Scottish Equity Partners Announces Investment in Dotmatics
News Nov 02, 2017
SEP is an informatics software provider delivering enterprise solutions tailored to the modern, highly collaborative and mobile scientific environments. Dotmatics provides solutions for pharmaceutical, biotechnology, academia, food and beverage, oil and gas, and agrochemical industries. The funding will enable Dotmatics to continue its investment into product innovation and customer success, as well as to strengthen operations in each of its key geographies.
Dotmatics’ comprehensive solutions include tools for knowledge management, data storage, enterprise querying and reporting, data analysis and visualisation. Headquartered in the UK, Dotmatics is one of the fastest growing global informatics companies and currently employs more than 100 people including chemists, biologists and software engineers across Europe, USA and Asia Pacific.
The investment deal was led by SEP partners Keith Davidson and Jan Rutherford. Keith Davidson said, “Dotmatics is a fast growing and capital efficient SaaS business, with an excellent reputation in the scientific research informatics market. The company has a strong focus on innovation and providing customers with first class scientific solutions and support. We have watched the company expand its customer base significantly over the course of the last few years and look forward to supporting its future growth plans.”
Stephen Gallagher, CEO of Dotmatics, commented, “We have grown rapidly and organically since inception and are pleased to have secured SEP as investors given the firm’s considerable software and health sector experience and their record of scaling companies. The funding will enable us to continue our aggressive trajectory in providing chemistry solutions, further expansion into biologics and increase our investment into customer support through strategic hires in application science product development and professional services.”
Towards Personalized Medicine: One Type of Data is Not EnoughNews
To understand the biology of diseased organs researchers use different types of molecular data. One of the biggest computational challenges at the moment is integrating these multiple data types. A new computational method jointly analyses different types of molecular data and disentangles the sources of disease variability to guide personalized treatment.READ MORE
PhoreMost and o2h Discovery Collaborate to Progress First-in-Class Drug Discovery ProgramsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage.READ MORE
Gene-edited Pigs are Resistant to Billion-dollar VirusNews
Scientists have produced pigs that can resist one of the world’s most costly animal diseases, by changing their genetic code. Tests with the virus – called Porcine Reproductive and Respiratory Syndrome, or PRRS – found the pigs do not become infected at all. The animals show no signs that the change in their DNA has had any other impact on their health or wellbeing.READ MORE